MedTrace Logo

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 254

Last updated 2025-07-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.

Conditions

  • Nonalcoholic Steatohepatitis (NASH)

Interventions

BIOLOGICAL

NGM282

OTHER

Placebo

Sponsors & Collaborators

  • NGM Biopharmaceuticals Australia Pty Ltd

    collaborator INDUSTRY

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • NGM Study Director · NGM Biopharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-12-06
Completion
2020-01-17

Countries

  • United States
  • Australia
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02443116 on ClinicalTrials.gov